Batch codes and associated deaths, disabilities and illnesses for Covid 19 Vaccines
Data Sources
- VAERS provided the number of deaths following vaccination with Pfizer for each state in the USA.
- The number of vaccinated in each state as of January 14th 2022 was provided by – number vaccinated. So I was able to calculate the number dying in each state per 100,000 vaccinated.
Observations
- There is considerable variation in the number dying per 100,000 vaccinated. Some states have 16 x the death rate compared to others.
- Red states tend to cluster towards the top of the chart, whilst blue states cluster towards the bottom.
- Red states occupy 6 of the 7 highest ranking positions for deaths per 100,000 vaccinated
Safety Signal
Some states, in particular Kentucky, Montana, Alaska, Tennessee, North Dakota and South Dakota are experiencing 4 x, 5 x, 6 x or even 11 x the number of deaths per 100,000 vaccinated compared to other states. Such a situation should be raising a safety signal, and requires investigation. The higher death rate in these states following vaccination suggests that they may be receiving more toxic batches, or being administered to more vulnerable people.
More Stories
Concerned Doctors with Dr. Albert Benavides
https://rumble.com/embed/v1ipffl/?pub=r2wmz Click Here to Enter Albert Benavides Dashboard
WHO HANDED THE KEYS TO FAUCI?!
https://www.bitchute.com/video/w2pPTZ67ikHH/ The Highwire with Del Bigtree The Highwire with Del Bigtree
SARS-CoV-2 Spike Proteins and Cell-Cell Communication Inhibits TFPI and Induces Thrombogenic Factos in Human Lung Microvascular Endothelial Cell and Neutrophils: Implications for COVID-19 Coagulopathy Pathogenisis
In SARS-CoV-2-infected humans, disease progression is often associated with acute respiratory distress syndrome involving severe lung injury, coagulopathy, and thrombosis of the alveolar capillaries. The pathogenesis of these pulmonary complications in COVID-19 patients has not been elucidated. Autopsy study of these patients showed SARS-CoV-2 virions in pulmonary vessels and sequestrated leukocytes infiltrates associated with endotheliopathy and microvascular thrombosis. Since SARS-CoV-2 enters and infects target cells by binding its spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2), and there is evidence that vascular endothelial cells and neutrophils express ACE2, we investigated the effect of S-proteins and cell–cell communication on primary human lung microvascular endothelial cells (HLMEC) and neutrophils expression of thrombogenic factors and the potential mechanisms. Using S-proteins of two different SARS-CoV-2 variants (Wuhan and Delta), we demonstrate that exposure of HLMEC or neutrophils to S-proteins, co-culture of HLMEC exposed to S-proteins with non-exposed neutrophils, or co-culture of neutrophils exposed to S-proteins with non-exposed HLMEC induced transcriptional upregulation of tissue factor (TF), significantly increased the expression and secretion of factor (F)-V, thrombin, and fibrinogen and inhibited tissue factor pathway inhibitor (TFPI), the primary regulator of the extrinsic pathway of blood coagulation, in both cell types. Recombinant (r)TFPI and a thiol blocker (5,5′-dithio-bis-(2-nitrobenzoic acid)) prevented S-protein-induced expression and secretion of Factor-V, thrombin, and fibrinogen. Thrombomodulin blocked S-protein-induced expression and secretion of fibrinogen but had no effect on S-protein-induced expression of Factor-V or thrombin. These results suggests that following SARS-CoV-2 contact with the pulmonary endothelium or neutrophils and endothelial–neutrophil interactions, viral S-proteins induce coagulopathy via the TF pathway and mechanisms involving functional thiol groups. These findings suggest that using rTFPI and/or thiol-based drugs could be a viable therapeutic strategy against SARS-CoV-2-induced coagulopathy and thrombosis. View Full-Text
Oro-Systemic Health Symposium 2022 – Part 3: Graham Lloyd-Jones – The anatomy of COVID-19
https://youtu.be/pPsbO1Qw2GM Dr. Graham Lloyd-Jones, Consultant Radiologist at Salisbury NHS Foundation Trust and Director of Radiology Masterclass, describes the nature of...